<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="11" ids="26333">Prostaglandin</z:chebi> (PG) E1 is a potent <z:chebi fb="1" ids="35620">vasodilator</z:chebi> on the peripheral vessels and also has an inhibitory action of platelet aggregation </plain></SENT>
<SENT sid="1" pm="."><plain>Lipo <z:chebi fb="0" ids="15544">PGE1</z:chebi>, the <z:chebi fb="23" ids="18059">lipid</z:chebi> emulsified <z:chebi fb="0" ids="15544">PGE1</z:chebi> has much longer half life time in the circulation than <z:chebi fb="0" ids="15544">PGE1</z:chebi> which is rapidly inactivated in the lung </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this investigation was to study the clinical and hemodynamic effect of Lipo <z:chebi fb="0" ids="15544">PGE1</z:chebi> on the 15 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011011'>subacute</z:hpo> focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Of these patients, five had evidence of internal carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp>, and ten had either occlusion or severe stenosis of middle cerebral artery </plain></SENT>
<SENT sid="4" pm="."><plain>Lipo <z:chebi fb="0" ids="15544">PGE1</z:chebi> containing 15 micrograms of <z:chebi fb="0" ids="15544">PGE1</z:chebi> was administered within 12 days of <z:hpo ids='HP_0003674'>onset</z:hpo> of ischemic events </plain></SENT>
<SENT sid="5" pm="."><plain>Before the first Lipo <z:chebi fb="0" ids="15544">PGE1</z:chebi> administration, regional cerebral blood flow (rCBF) of the affected middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) territory was 41.8 +/- 8.4 ml/100 g/min and on the non-affected side was 60.0 +/- 9.4 ml/100 g/min </plain></SENT>
<SENT sid="6" pm="."><plain>Immediately after the Lipo <z:chebi fb="0" ids="15544">PGE1</z:chebi> treatment, rCBF of the <z:chebi fb="70" ids="34342">MCA</z:chebi> region was increased by 6% on the affected side and by 11% on the non-affected side </plain></SENT>
<SENT sid="7" pm="."><plain>rCBF of the affected <z:chebi fb="70" ids="34342">MCA</z:chebi> territory was increased more than 15% in five cases (Group 1) and was changed less than +/- 15% in seven cases (Group 2) by the first Lipo <z:chebi fb="0" ids="15544">PGE1</z:chebi> treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Lipo <z:chebi fb="0" ids="15544">PGE1</z:chebi> was administered every 8 hours for 10 to 14 days in these 12 cases </plain></SENT>
<SENT sid="9" pm="."><plain>By the continuous Lipo <z:chebi fb="0" ids="15544">PGE1</z:chebi> treatment, rCBF of the affected <z:chebi fb="70" ids="34342">MCA</z:chebi> territory increased by 18% in the Group 1 and by 3% in the Group 2.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>